Cerebral palsy (CP) is a condition affecting young children that causes lifelong disabilities. Umbilical cord blood cells improve motor function in experimental systems via paracrine signaling. After demonstrating safety, we conducted a phase II trial of autologous cord blood (ACB) infusion in children with CP to test whether ACB could improve function (ClinicalTrials.gov, NCT01147653; IND 14360). In this double-blind, placebo-controlled, crossover study of a single intravenous infusion of 1–5 × 10^7 total nucleated cells per kilogram of ACB, children ages 1 to 6 years with CP were randomly assigned to receive ACB or placebo at baseline, followed by the alternate infusion 1 year later. Motor function and magnetic resonance imaging brain connectivity studies were performed at baseline, 1, and 2 years post-treatment. The primary endpoint was change in motor function 1 year after baseline infusion. Additional analyses were performed at 2 years. Sixty-three children (median age 2.1 years) were randomized to treatment (n = 32) or placebo (n = 31) at baseline. Although there was no difference in mean change in Gross Motor Function Measure-66 (GMFM-66) scores at 1 year between placebo and treated groups, a dosing effect was identified. In an analysis 1 year post-ACB treatment, those who received doses ≥2 × 10^7/kg demonstrated significantly greater increases in GMFM-66 scores above those predicted by age and severity, as well as in Peabody Developmental Motor Scales-2 Gross Motor Quotient scores and normalized brain connectivity. Results of this study suggest that appropriately dosed ACB infusion improves brain connectivity and gross motor function in young children with CP.

SIGNIFICANCE STATEMENT

Results of this trial suggest that, when adequately dosed, an intravenous infusion of autologous umbilical cord blood improves whole brain connectivity and motor function in young children with cerebral palsy.
placebo-controlled trial testing the efficacy of a single IV ACB infusion in young children with CP.

**MATERIALS AND METHODS**

**Study Design**

We conducted a single-center, phase II, prospective, randomized, double-blind, placebo-controlled, crossover study of a single IV ACB infusion in children ages 1 to 6 years with CP (Fig. 1) at Duke University. The study was approved by the Duke Institutional Review Board and conducted under FDA IND14360.

**Participants**

Eligible children were 1 to 6 years old had CP with (a) Gross Motor Classification System (GMFCS) level 2–4 or (b) GMFCS level 1 with hemiplegia if they used their affected hand as an assist only. Children also had to have an eligible ACB unit banked at a public or private cord blood bank that was sterile, had a precryopreservation total nucleated cell count (TNCC) ≥1 × 10^7/kg, and met criteria in Table 1. Children with genetic conditions, intractable seizures, hypsarrhythmia, athetoid CP, severe microcephaly, autism without motor disability, evidence of a progressive neurologic disease or a condition that could require a future allogeneic stem cell transplant, active infection(s), impaired renal, liver or respiratory function, or a history of prior cell therapy were ineligible. Written informed consent was obtained from parent(s)/guardian(s) for patient and ACB screening and study participation.

**Randomization and Masking**

Patients were randomized to the order in which they received ACB and placebo infusions, given 1 year apart. Those on the ACB arm received an infusion of ACB at baseline. Those on the placebo arm received an infusion of a placebo solution constructed to mimic the color and smell of the ACB at baseline. The placebo product consisted of TC-199 1% dimethyl sulfoxide (DMSO). Computer-generated randomization was performed by The Emmes Corporation in a 1:1 ratio, stratified by age and CP typography. Only staff preparing the products were aware of the treatment assignment, and these individuals had no contact with the patients, families, providers, and examiners who were masked to the assigned treatment. Masking was achieved by covering all infusion bags with a dark bag in the laboratory and infusing a similar volume as the placebo product. Cell dose, targeted at 1–5 × 10^7 cells per kilogram, was not randomly assigned, but was determined by the number of cells available in each ACB unit and the patient’s weight.

**Procedures**

Patients’ medical records and ACB reports were reviewed. If likely to be eligible, an ACB sample was shipped to Duke for potency

---

**Table 1. Qualifying characteristics of autologous umbilical cord blood units**

| Characteristic                                      | Specification                      |
|-----------------------------------------------------|------------------------------------|
| Precryopreservation characteristics                 |                                    |
| Total nucleated cell count                           | ≥1 × 10^7/kg                       |
| Viability (total or CD34)                            | ≥80%                               |
| Sterility culture                                    | Negative                           |
| Maternal infectious disease screening^a               | Negative                           |
| Test sample available for confirmatory HLA typing   | Yes                                |

**Cord blood test sample characteristics**

| Identity confirmation via HLA testing of subject and cord blood sample | Confirmed |
| CD34 viability                                                        | ≥60%      |
| Colony-forming units                                                  | Growth    |

^aAll mothers/units were tested for Hepatitis B, Hepatitis C, HIV, and syphilis. Most were also tested for HTLV I/II. Abbreviation: HLA, human leukocyte antigen.
and viability testing. Unit identity was confirmed by low-resolution Human Leukocyte Antigen (HLA)-testing of patient and ACB samples. If specifications were met, the cryopreserved ACB unit was shipped to Duke and stored under liquid nitrogen until the day of ACB infusion. Prior to enrollment, all patients were assessed by an independent examiner (M.A.M., G.W., R.G.) to confirm eligibility and assign baseline GMFCS level. On the day of ACB infusion, the product was thawed and washed in dextran 40 + 5% albumin (DA) and placed in 1.25 ml/kg DA for administration [5]. Placebo infusions consisted of TC-199 + 1% (DMSO). The cells or placebo were administered at baseline and 1 year later in a masked manner through a peripheral IV catheter over 5–15 minutes in the outpatient setting after premedication with oral acetaminophen (10–15 mg/kg), IV diphenhydramine (0.5 mg/kg), and IV methylprednisolone (0.5 mg/kg). Subjects received maintenance IV fluids and were monitored for 2–4 hours post-infusion. Safety endpoints were incidences of infusion reactions and infections related to the study treatment. Safety assessments were conducted at 24 hours and 7–10 days after each infusion, as well as annually during return visits. Participants received traditional rehabilitation therapies per their local physicians and therapists throughout the duration of the study.

Motor Assessments

Functional assessments were performed by trained physicians and therapists at baseline, 1-year, and 2-years. GMFCS level was assessed and motor evaluations completed, including the Peabody Motor Assessments [6] and GMFM-66 [7], a 66-item measure designed to assess gross motor function in children with CP.

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) was performed, under moderate sedation for most participants, at baseline, 1-year, and 2-years. Diffusion weighted images were acquired on a 3 Tesla GE MR750 scanner (Waukesha, WI) using a 25-direction gradient diffusion encoding scheme (b = 1,000 seconds/mm², 3 non-diffusion-weighted images), 70.5 ms echo time (TE), and 12,000 millisecond repetitions time (TR). Isotropic resolution of 2 mm³ was achieved using a 96 × 96 acquisition matrix in a field of view (FOV) of 192 × 192 mm². T2-weighted images were obtained with an inversion-prepared three-dimensional (3D) fast spoiled-gradient-recalled (FSPGR) pulse sequence with a 2.5 ms TE, 450 ms inversion time (TI), 6.5 ms TR, and 12° flip angle, at 1 mm³ isotropic resolution.

Whole brain connectome analysis was based on MRI diffusion weighted images from all directions. Diffusion tensor in every voxel across the entire brain was derived, and fiber pathways tracked using fiber assignment by continuous tracking streamline tracking algorithm [8, 9] based on a standard fractional anisotropy (FA) threshold (0.2) to limit the pathways within the white matter. A whole-brain connectome analysis, based on all diffusion tensors, was then carried out to investigate brain connectivity and improvement among functional brain regions. These gray matter regions, termed “nodes” in the brain connectome, were defined by the JHU-DTI-MNI “Eve” atlas template [10, 11], and warped into each subject’s DTI image space via the Advanced Normalization Tools toolkit [12] for a standardized processing strategy. Connectivity from any given node, or between any pair of nodes, was first measured by determining volumes of the relevant white matter fiber pathways projecting from that node or between a pair of nodes. These volumes were then further normalized by the total white matter volume (derived from a 3D FSPGR T1 weighted MRI) to remove the dependence on brain sizes due to developmental effect.

Statistical Analysis

The primary endpoint was change in motor function from baseline to 1-year assessed by the GMFM-66. A positive change in GMFM-66 score is considered an improvement, and minimal clinically important differences (MCIDs) [13] of medium and large effect sizes have been established. Sample size planning used estimates of this change score in untreated patients derived from a literature review (mean = 6, SD = 3) [14, 15]. The study was originally planned for 60 subjects/group (n = 120 total), estimated to provide 78%–97% power to detect a clinically relevant increase of 25%–35% in the mean 1-year GMFM-66 change score comparing ACB to placebo using a two-sided, equal-variance t test and 5% Type I error rate.

Two unplanned interim analyses were conducted for the primary endpoint. Efficacy stopping rules were designed to preserve the overall Type I error rate at 5% using an alpha spending function, \( f(t) = \min\{\alpha t^3, \alpha \} \). The null hypothesis of no difference between treatment groups was not rejected at either analysis. A simulation study for conditional power conducted after the first interim analysis suggested potential benefit in continuing the trial. However, due to slow accrual, the trial was closed when enrollment reached \( n = 63 \). When all subjects had completed the 1-year assessment and after verifying assumptions, the test of the primary hypothesis was performed using an equal-variance, two-sample \( t \) test with a critical value of 2.00, which maintained an overall two-sided cumulative alpha of 0.05 across interim looks with the final sample size. Results of the interim analyses were reviewed by the primary investigators. Study personnel conducting outcome assessments were not informed of the results.

All analyses (performed by B.B., J.T., R.S. using SAS versions 9.3 and 9.4) followed the intention-to-treat principle. The primary endpoint was compared between ACB and placebo using an equal-variance \( t \) test. Additional analyses, involving comparison of outcomes by dose between ACB and placebo 1 year after baseline and among all patients 1 year after treatment with ACB, used the \( t \) test, Wilcoxon rank sum test, Fisher’s exact test, or Spearman correlation as appropriate. We defined high- and low-dose categories using the cohort median dose. For analyses from baseline to 1 year, the median dose was calculated for the 32 patients randomized to the treatment arm (3.0 × 10^7/kg precryopreservation, 1.98 × 10^7/kg infused). For analyses of the composite cohort (all children 1 year post ACB infusion), we used the median infused dose for all 63 patients, 2 × 10^7/kg. Data for this report were locked on October 25, 2016. This trial is registered with ClinicalTrials.gov, number NCT01147653.

Results

Characteristics of Patients and ACB Units

Between September 27, 2010 and February 14, 2014, 63 patients were enrolled and randomized to receive an initial infusion of ACB (\( n = 32 \)) or placebo (\( n = 31 \)) with a crossover to the alternate infusion 1 year later (Fig. 1). Subjects’ etiology of CP was classified as: periventricular leukomalacia (\( n = 17 \)), in utero stroke/bleed (\( n = 27 \)), ischemic injury (\( n = 7 \)), other multifactorial causes
containing a CD34 of the ACB unit was used for infusion and the remainder was cryopreservation or infused doses of 3 \times 10^7/kg (range 0.05–4.9 \times 10^7/kg) and 3.91 (0.04–36.21) \times 10^5/kg (range 0.00–15.5). ACB unit characteristics are shown in Table 2.

### Safety of ACB Infusions

Infusions of thawed ACB and placebo products, both containing DMSO, were well tolerated, and there were no serious adverse events related to the infusions. One patient had transient infusion reactions consisting of hives and low-grade fever after both placebo and ACB infusions, successfully treated with additional diphenhydramine. Despite negative precryopreservation cultures, one ACB unit grew *Streptococcus* from a sample of the thawed unit. That patient was not treated with antibiotics and did well.

### GMFCS Level

Table 2. Characteristics of patients and autologous cord blood units by randomized treatment assignment and cell dose

| Characteristics                  | Autologous Cord blood group (N = 32) | Placebo group (N = 31) | Infused cell dose |
|----------------------------------|--------------------------------------|------------------------|-------------------|
|                                  |                                      |                        | Low (<2 \times 10^7/kg) (N = 31) | High (>2 \times 10^7/kg) (N = 32) |
| Age, years – median (range)      | 2.1 (1.1–6.2)                        | 2.3 (1.1–7.0)          | 2.5 (1.1–7.0)     | 2.1 (1.1–5.3) |
| Sex – no. (%)                    |                                       |                        |                   |                   |
| Male                             | 20 (62.5)                            | 22 (71)                | 20 (64.5)         | 22 (68.8)         |
| Female                           | 12 (37.5)                            | 9 (29)                 | 11 (35.5)         | 10 (31.3)         |
| Race – no. (%)                   |                                       |                        |                   |                   |
| White                            | 27 (84.4)                            | 28 (90.3)              | 26 (83.9)         | 29 (90.6)         |
| Non-white                        | 5 (15.6)                             | 3 (9.7)                | 5 (16.1)          | 3 (9.4)           |
| Type of cerebral palsy – no. (%) |                                       |                        |                   |                   |
| Hypotonic quadriplegia           | 1 (3.1)                              | 3 (9.7)                | 2 (6.5)           | 2 (6.3)           |
| Spastic diplegia                 | 6 (18.8)                             | 6 (19.4)               | 7 (22.6)          | 5 (15.6)          |
| Spastic hemiplegia               | 15 (46.9)                            | 15 (48.4)              | 12 (38.7)         | 18 (56.3)         |
| Spastic quadriplegia             | 10 (31.3)                            | 7 (22.6)               | 10 (32.3)         | 7 (21.9)          |
| GMFCS level – no. (%)            |                                       |                        |                   |                   |
| I/II                             | 21 (65.6)                            | 21 (67.7)              | 18 (58.1)         | 24 (75.0)         |
| III/IV                           | 11 (34.4)                            | 10 (32.3)              | 13 (41.9)         | 8 (25.0)          |
| Baseline GMFM-66 score – mean (SD) | 48.9 (16.2)                     | 52.0 (15.7)            | 48.9 (20.3)       | 51.9 (10.1)       |

**Note:**

- Difference between dosing groups is not statistically significant.
- All cord blood characteristics except CFU dose are statistically significant between doing groups (p < .01) and not statistically different between randomized groups.

Abbreviation: CFU, colony-forming unit; GMFM-66, Gross Motor Function Measure-66; GMFCS, Gross Motor Function Classification System; TNCC, total nucleated cell count.

(n = 12). Of these 12 patients, etiologies and MRI findings were highly variable and included two patients who were born premature, one with a porencephalic cyst, three with white matter abnormalities, five with normal MRIs, and one of unclear etiology. One-third of patients had moderately severe GMFCS levels (3–4) at study entry. Treatment groups were balanced with respect to age, sex, race, type, and severity of CP (Table 2).

ACB units were retrieved from 16 international cord blood banks. All subjects received all infusions as intended. The median precryopreservation TNCC of banked ACB units was 4.9 \times 10^8. To achieve the target TNCC dose of 1–5 \times 10^7/kg, the entire ACB unit was used in 31 patients. In the other 32 patients for whom the cell dose from the whole ACB unit would have exceeded the dosing range, a portion of the ACB unit was used for infusion and the remainder was cryopreserved and stored for potential future use. Post-thaw, a median of 2 \times 10^7 TNCC/kg were administered (range 0.38–5.03 \times 10^7/kg), containing a CD34+ dose of 0.5 \times 10^7/kg (range 0.05–4.9 \times 10^7/kg). ACB unit characteristics are shown in Table 2.

**GMFCS Level**

Change in GMFCS level at study entry [16]. However, subjects randomized to ACB who were treated with TNCC doses above the median precryopreservation or infused doses of 3 \times 10^7/kg and 1.98 \times 10^7/kg, respectively, demonstrated statistically significant, clinically meaningful improvement in GMFCS-66 change scores, above MCIDs, compared with subjects who received lower cell doses (p < .01 for precryopreservation dose, p = .05 for infused dose) or placebo (p = .02 for precryopreservation dose) (Fig. 2B).
doses were not associated with baseline age or type/severity of CP (Table 2). In the placebo group, change from baseline to 1 year was not associated with the precryopreservation cell dose available in the subjects’ ACB unit (not shown). CD34 cell doses were not associated with motor improvement.

To examine the effect of cell dose and to adjust response for the natural history of expected gains based on baseline GMFCS levels and GMFM-66 scores of each subject, we used published percentiles [16] to compare the actual GMFM-66 score change to the predicted change. The difference between the observed 1-year GMFM-66 score and the predicted 1-year GMFM-66 score was then calculated. Since percentile values are only available for children ≥2 years, this analysis included the 38 patients who were ≥2 years old at study entry. There was no significant difference in the median observed-expected difference in GMFM-66 scores at 1 year in patients randomized to ACB (n = 19; 1.7; IQR −2.5 to 4.5) versus placebo (n = 19; 2.2; IQR 0.0 to 3.0; p = .99). However, in an exploratory analysis, subjects who received a TNCC ≥210^7/kg (n = 9) improved a median of 4.3 points (IQR 2.8–5.9) greater than expected, and this change was statistically significantly different from that observed in subjects who received <210^7/kg (n = 10; median 1.9, IQR −3.9 to 1.7; p = .02) or placebo (n = 19; median 2.2, IQR 0.0 to 3.0; p = .05, Fig.2C), with improvement above the MCID of large effect size.

We then used the 2-year data to further explore the effect of cell dose by comparing the difference between observed and expected GMFM-66 scores 1 year after ACB infusion in all subjects who were ≥2 years old when they were treated (n = 46), regardless of when the infusion was given (baseline or 1 year). In this analysis, the dose relationship from the primary analysis was confirmed: subjects who received ≥210^7 cells per kg (n = 23) improved a median 3.6 points (IQR 2.0 to 4.5) greater than expected, whereas subjects who received <210^7/kg did not improve beyond expectation (median 1.1, IQR −3.7 to 1.3, p = .003, Fig. 3A).

**PDMS-2 Results**

At 1 year post initial treatment (ACB vs. placebo), 50 patients were eligible for analysis of the PDMS-2 Gross Motor Quotient, which assesses gross motor skills in young children from birth to 72 months of age. Of note, eight subjects excluded from analysis of observed-expected GMFM-66 scores due to age (<2 years) were included in the PDMS analysis. The median change from baseline did not differ significantly between randomized groups...
 Improvement compared with subjects receiving lower doses (median [IQR]: high-dose 3.0 [−2.0 to 9.0] vs. low-dose 0 [−4.0 to 2.0], \( p = .02 \), Fig. 3B).

**Imaging Results**

We explored relationships between motor response, total brain connectivity, and cell dose. Accurate anatomical image

---

*Figure 3.* Gross motor function and brain connectivity 1 year after autologous cord blood treatment by cell dose. High dose \( \geq 2 \times 10^7/\text{kg} \), low dose \(< 2 \times 10^7/\text{kg} \). (A): Observed-Expected GMFM-66 scores 1 year after treatment in patients \( \geq 2 \) years of age at the time of ACB infusion. (B): Peabody Developmental Motor Scales-2 gross motor change scores 1 year after treatment. (C): Change in normalized whole brain connectivity 1 year after treatment. (D): Connectome representation. The nodes and edges included are those that demonstrated significantly increased improvement in children receiving high doses compared with those receiving low doses, as indicated by the color chart, with insignificant nodes shown in gray. Representative nodes in the sensorimotor network with significant changes correlated with improvement in GMFM-66 scores include the pre- and post-central gyri, basal ganglia, and brain stem. Abbreviation: GMFM-66, Gross Motor Function Measure-66.
parcellation could not be obtained in approximately one-third of subjects due to injury that distorted normal brain morphology, leaving 23 treated and 15 placebo patients with evaluable connectivity data (n = 38). Data from 17 of these subjects has been reported previously [17]. There were no statistically significant differences in CP type, GMFCS level, or age between patients with and without analyzable images.

There was a moderate correlation between change in GMFM-66 score and total connectivity 1 year after baseline in all analyzable subjects (n = 38, Spearman r = 0.53; 95% CI: 0.25, 0.73; p < .001). In this cohort, total connectivity change was not related to baseline GMFCS level, typography of CP, or sex, but was inversely correlated with age (Spearman r = −0.52; 95% CI: −0.72, −0.23; p = .001). In the 2-year analysis when all evaluable subjects were examined by cell dose, patients who received ≥2 × 10^7 TNCC/kg (n = 19) demonstrated a statistically significant greater increase in normalized whole brain connectivity 1 year after treatment than children who received lower doses (n = 19; P = .04, Fig. 3C). In the sensorimotor network, nodes with significant increases in connectivity that correlated with improvement in GMFM-66 scores included the pre- and post-central gyri, basal ganglia, and brain stem.

**Discussion**

We tested whether a single IV infusion of ACB could improve GMFM-66 change scores in young children with CP. We observed that children who received higher cell doses (≥2 × 10^7/kg infused) demonstrated superior gains in both whole brain connectivity and motor function 1 year after infusion of ACB. Based on preclinical models, we hypothesized that ACB acts through homologous paracrine signaling, rather than cellular integration or engraftment of infused cells.

There are some limitations of this study. The first is the small sample size and heterogeneity of patients within groups. Also, in this study cohort, both randomized groups including placebo patients experienced gains in motor function above those predicted by the GMFM-66. This may reflect the impact of developmental therapies and other interventions in the highly motivated and resourced families who participated in this study. Nonetheless, the median change in GMFM-66 score in the high-dose group (8.5, IQR 5.5–14.5), exceeded that of the low-dose (4, IQR 0.0–10.0) and placebo (6, IQR 3.0–11.0) groups by more than established MCIDs [18], indicating a statistically significant and clinically meaningful difference between dosing groups. These responses were not correlated with age or type, etiology, or severity of CP.

The observation that children receiving cell doses ≥2 × 10^7/kg had a response is important. As a therapeutic dose had not been established in this setting, we targeted a TNCC 1–5 × 10^7/kg based on safety data for this range in children undergoing allogeneic cord blood transplantation. However, in additional analyses, we observed that children with CP demonstrated statistically significant improvement in gross motor function on two well-validated measures (GMFM-66, PDMS) when ACB was administered at doses (3 × 10^7/kg precyopreservation and 2 × 10^7/kg infused) that are above the threshold for hematopoietic reconstitution in allogeneic transplantation [18]. This finding is consistent with two other randomized trials of cell therapy in children with CP, both conducted in Korea using allogeneic cord blood [19, 20]. One study demonstrated greater improvement on select motor and cognitive scales six months after treatment in patients who received a precyopreservation TNCC ≥3 × 10^7/kg + erythropoietin versus those who received erythropoietin alone or placebo. They also noted a dose correlation, with higher doses associated with greater improvement [19]. The second study showed similar results in 36 children treated with cord blood or placebo [20].

Important relationships were also detected via whole brain connectome analysis of MRI/DTI data, an objective measure of whole brain connectivity including the motor network, suggesting that improvements in motor function result from increased or new connectivity induced by paracrine signaling of ACB cells. We confirmed that increased total brain connectivity is correlated with increased motor improvement, as reported by our previous studies [17]. Furthermore, we also showed that compared with children who received a low cell dose, children who received a dose ≥2 × 10^7/kg demonstrated a greater increase in both normalized total brain connectivity and changes in the sensorimotor network, including the pre- and post-central gyri, deep gray matter, and brain stem (Fig. 3) 1 year post-treatment with ACB. Although the primary manifestation of CP is motor in nature, it is well known that CP can affect multiple aspects of development and in many cases is a whole-brain disorder. Thus, whole brain connectivity, along with graphical analysis of the brain connectome including the motor network, may serve as a biomarker of treatment response and may help elucidate the mechanism of action of ACB therapy in this patient population.

In the course of conducting this study, we were contacted by hundreds of families of children with CP who did not have a qualified ACB unit available. If umbilical cord blood is indeed established as a source of cells for restorative therapies, a method to provide treatment to such individuals will be necessary. As the hypothesized mechanism of action—that cells contained in ACB act on endogenous cells in the brain via paracrine signaling to enhance brain connectivity and thus function—does not require engraftment or integration of infused cells, it is feasible that donor cord blood cells may be equally efficacious. Therefore, we plan to study the safety and efficacy of allogeneic cell sources in future studies.

**Conclusion**

Results of this trial suggest that when dosed ≥2 × 10^7 cells per kg, an IV infusion of ACB improves whole brain connectivity and motor function in young children with CP. These findings have important implications for the treatment of children with CP and should be further explored in future studies. As it is not feasible for every child to have an available ACB unit, studies of allogeneic cord blood should also be pursued.

**Acknowledgments**

The costs of all treatment and studies in this clinical trial were supported by generous grants from The Julian Robertson Foundation and The Marcus Foundation, without which this work could not have been done. We thank the administrative staff and the clinical trials associates from the Robertson Clinical and Translational Cell Therapy Program at Duke for their work on behalf of this study. We are indebted to the patients and families for their dedication and commitment to participating in this trial.
**AUTHOR CONTRIBUTIONS**

J.M.S. and J.K.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of the manuscript; A.W.S.: collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of the manuscript; L.E.C.: collection and/or assembly of data, final approval of the manuscript; M.A.M.: conception and design, collection and/or assembly of data, final approval of the manuscript; K.E.G.: conception and design, collection and/or assembly of data; R.S.: data analysis and interpretation, final approval of the manuscript; R.G. and G.W.: conception and design, collection and/or assembly of data, final approval of the manuscript; J.P., C.M., and B.W-P.: collection and/or assembly of data, final approval of the manuscript; J.T.: data analysis and interpretation, final approval of the manuscript; K.E.G.: conception and design, collection and/or assembly of data, final approval of the manuscript; L.W.C., S.W., and B.B.: data analysis and interpretation, final approval of the manuscript; R.G. and G.W.: conception and design, collection and/or assembly of data, final approval of the manuscript; R.G. and G.W.: conception and design, collection and/or assembly of data, final approval of the manuscript; J.P., C.M., and B.W-P.: collection and/or assembly of data, final approval of the manuscript; J.T.: data analysis and interpretation, final approval of the manuscript.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors report grant funding from The Julian Robertson Foundation (PI: J.K.), The Marcus Foundation (PI: J.K.), The Dana Foundation (PI: J.M.S.), and the NIH (PI: A.W.S.), and fees from Duke University (B.B., S.W.). J.K. serves as the Director of the Carolinas Cord Blood Bank, a public cord blood bank located at Duke University. J.K. and J.M.S. have a patent pending for Cord Blood Therapy for Cerebral Palsy. S.W. and B.B. are employees of The Emtes Corporation and received research funding from Duke University. J.D.T. is a consultant to the Emmes Corporation, has honorarium for serving on DSMB for Gamida Cell, and research funding from Seattle Genetics. The other authors indicated no potential conflicts of interest.

**REFERENCES**

1. Arneson CL, Durkin MS, Benedict RE et al. Prevalence of cerebral palsy: Autism and Developmental Disabilities Monitoring Network, three sites, United States, 2004. Disabil Health J 2009;2:45–48.
2. Drobyshevsky A, Cotten CM, Shi Z et al. Human umbilical cord blood cells ameliorate motor deficits in rabbits in a cerebral palsy model. Dev Neurosci 2015;37:349–362.
3. Meier C, Middelans J, Wasielewski B et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res 2006;59:244–249.
4. Sun J, Allison J, McLaughlin C et al. Differences in quality between privately and publicly banked umbilical cord blood units: A pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010;50:1980–1987.
5. Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of peripheral blood mononuclear cells. Pediatr Blood Cancer 2005;45:101–108.
6. Folio MR. PDMS-2: Peabody Developmental Motor Scales. 2nd ed. Austin: Pro-Ed, 2000.
7. Russell DJ. Gross motor function measure (GMFM-66 & GMFM-88) user’s manual. London: Mac Keith, 2002.
8. Mori S, Crain BJ, Chacko VP et al. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol 1999;45:265–269.
9. Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006;51:527–539.
10. Oishi K, Faria A, Jiang H et al. Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: Application to normal elderly and Alzheimer’s disease participants. Neuroimage 2009;46:486–499.
11. Faria AV, Hoon A, Stashinko E et al. Quantitative analysis of brain pathology based on MRI and brain atlases-applications for cerebral palsy. Neuroimage 2011;54:1854–1861.
12. Avants BB, Tustison NJ, Song G et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011;54:2033–2044.
13. Oeffinger D, Bagley A, Rogers S et al. Outcome tools used for ambulatory children with cerebral palsy: Responsiveness and minimum clinically important differences. Dev Med Child Neurol 2008;50:918–925.
14. Rosenbaum PL, Walter SD, Hanna SE et al. Prognosis for gross motor function in cerebral palsy: Creation of motor development curves. JAMA 2002;288:1357–1363.
15. Russell DJ, Avery LM, Rosenbaum PL et al. Improved scaling of the gross motor function measure for children with cerebral palsy: Evidence of reliability and validity. Phys Ther 2000;80:873–885.
16. Hanna SE, Bartlett DJ, Rivard LM et al. Reference curves for the Gross Motor Function Measure: Percentiles for clinical description and tracking over time among children with cerebral palsy. Phys Ther 2008;88:596–607.
17. Englander ZA, Sun J, Laura C et al. Brain structural connectivity increases concurrent with functional improvement: Evidence from diffusion tensor MRI in children with cerebral palsy during therapy. Neuroimage Clin 2015;7:315–324.
18. Rubinstein P, Stevens CE. Placental blood for bone marrow replacement: The New York Blood Center’s program and clinical results. Baillieres Best Pract Res Clin Haematol 2000;13:565–583.
19. Min K, Song J, Kang JY et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A double-blind, randomized, placebo-controlled trial. Stem Cells 2013;31:581–591.
20. Kang M, Min K, Jang J et al. Improvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy. Stem Cells Dev 2015;24:2259–2268.